Salirasib has been used as a farnesyltransferase inhibitor.

Salirasib (Farnesylthiosalicylic acid) is a RAS inhibitor that acts by dislodging the farnesylated protein from the membrane, facilitating Ras degradation. Salirasib impairs downstream signaling and suppresses growth and migration of proliferating tumor cells in in vitro and in vivo models. Salirasib (Farnesylthiosalicylic acid) has recently been shown to possess significant anti-inflammatory and anti-arthritic properties.

Salirasib (Farnesylthiosalicylic acid) is a RAS inhibitor.

Salirasib (S-trans,trans-Farnesylthiosalicylic Acid /FTS) is a synthetic small molecule that has an ability to block all forms of Ras, unlike farnesyltransferase inhibitors, which fail to inhibit K-Ras and N-Ras function due to alternative membrane-binding mechanisms. Salirasib along with gemcitabine, exhibits anti-tumor activity and biomarker modulation in preclinical models of metastatic pancreatic adenocarcinoma (PDA). It is also used as a potent therapeutic for lung cancer.